Yvon van Delft

926 citations

28 papers · 481 indexed · h-index 12

Co-authors: Christiane Moecklinghoff José Ramón Arribas Mark Nelson Nathan Clumeck Andrew Hill Federico Pulido Thomas Stark Andrzéj Horban
Topics: HIV/AIDS drug development and treatment (25 papers)HIV Research and Treatment (24 papers)HIV/AIDS Research and Interventions (15 papers)
Cited by: Virology Infectious Diseases Emergency Medicine
Journals: PLoS ONE AIDS Journal of Antimicrobial Chemotherapy
Partner nations: Netherlands United Kingdom Germany

In The Last Decade

Yvon van Delft

27 papers receiving 474 citations

Peers

Countries citing papers authored by Yvon van Delft

Since Specialization

Citations

This map shows the geographic impact of Yvon van Delft's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yvon van Delft with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yvon van Delft more than expected).

Fields of papers citing papers by Yvon van Delft

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yvon van Delft. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yvon van Delft. The network helps show where Yvon van Delft may publish in the future.

Co-authorship network of co-authors of Yvon van Delft

This figure shows the co-authorship network connecting the top 25 collaborators of Yvon van Delft. A scholar is included among the top collaborators of Yvon van Delft based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yvon van Delft. Yvon van Delft is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Switching at Low HIV-1 RNA into Fixed Dose Combinations: TDF/FTC/RPV is non-inferior to TDF/FTC/EFV in first-line suppressed patients living with HIV 2019 ·Southern African Journal of HIV Medicine ·Paula Munderi,Edwin Were,Anchalee Avihingsanon,(unknown),Lerato Mohapi,(unknown),(unknown),(unknown),(unknown),Yvon van Delft	3
2	Efficacy of Once Daily Darunavir/Ritonavir in PI-Naïve, NNRTI-Experienced Patients in the ODIN Trial 2015 ·AIDS Research and Treatment ·Anna María Geretti,(unknown),Ralph DeMasi,Yvon van Delft,(unknown)	2
3	No Difference in the Rate of Change in Telomere Length or Telomerase Activity in HIV-Infected Patients after Three Years of Darunavir/Ritonavir with and without Nucleoside Analogues in the MONET Trial 2014 ·PLoS ONE ·Ajantha Solomon,Surekha Tennakoon,Edwin Leeansyah,José Ramón Arribas,Andrew F. Hill,Yvon van Delft,Christiane Moecklinghoff,Sharon R. Lewin	11
4	The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV‐1 RNA below 50 copies/mL 2014 ·Journal of the International AIDS Society ·Andrea Antinori,José Ramón Arribas,Jan Fehr,(unknown),Andrzéj Horban,Andrew Hill,Yvon van Delft,Christiane Moecklinghoff	15
5	Etravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials 2014 ·AIDS Research and Treatment ·Mark Nelson,Andrew Hill,Yvon van Delft,Christiane Moecklinghoff	6
6	Pharmacokinetics and Pharmacodynamics of Etravirine 400 mg Once Daily in Treatment-Naïve Patients 2013 ·HIV Clinical Trials ·Giovanni Di Perri,Bruce Green,Glynn Morrish,Andrew Hill,Gerd Faetkenheuer,Markus Bickel,Yvon van Delft,Michael Kurowski,Thomas N. Kakuda	5
7	Can we stop CD4+ testing in patients with HIV-1 RNA suppression on antiretroviral treatment? 2013 ·AIDS ·Pierre‐Marie Girard,Mark Nelson,(unknown),Andrew F. Hill,Yvon van Delft,Christiane Moecklinghoff	27
8	Dynamics of Cellular HIV-1 DNA Levels Over 144 Weeks of Darunavir/Ritonavir Monotherapy Versus Triple Therapy in the MONET Trial 2013 ·HIV Clinical Trials ·Anna María Geretti,José Ramón Arribas,Erkki Lathouwers,Geraldine M. Foster,(unknown),Sabine Kinloch,Andrew F. Hill,Yvon van Delft,Christiane Moecklinghoff	24
9	Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two‐panel, two‐way, two‐period, randomized trial 2013 ·HIV Medicine ·Thomas N. Kakuda,Ralph DeMasi,Yvon van Delft,(unknown)	15
10	Impact of baseline HIV‐1 RNA levels on initial highly active antiretroviral therapy outcome: a meta‐analysis of 12,370 patients in 21 clinical trials* 2012 ·HIV Medicine ·Christoph Stephan,Andrew Hill,W. A. Sawyer,Yvon van Delft,Christiane Moecklinghoff	22
11	Changes in Patient-reported Neuropsychiatric Outcomes during the SENSE Trial: First-line Treatment with Two Nucleoside Analogues plus Etravirine or Efavirenz 2012 ·Chloe Orkin,Mark Nelson,Christine Katlama,Philippe Morlat,Hansjakob Furrer,Yvon van Delft,(unknown),Andrew Hill,(unknown)	4
12	The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV‐1 RNA copies/mL at baseline 2012 ·HIV Medicine ·José Ramón Arribas,Nathan Clumeck,Mark Nelson,Andrew Hill,Yvon van Delft,Christiane Moecklinghoff	73
13	Predictors of long‐term HIV RNA suppression on darunavir/ritonavir monotherapy in the MONET trial 2012 ·Journal of the International AIDS Society ·José Ramón Arribas,Federico Pulido,(unknown),Yvon van Delft,Christiane Moecklinghoff	1
14	Impact of hepatitis C co-infection on response to antiretroviral treatment. 2012 ·PubMed ·Federico Pulido,Andrew Hill,Yvon van Delft,Christiane Moecklinghoff	13
15	96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baseline 2011 ·Journal of Antimicrobial Chemotherapy ·Nathan Clumeck,(unknown),Dénes Bánhegyi,Wolfgang Schmidt,A.D. Hill,Yvon van Delft,Christiane Moecklinghoff,José Ramón Arribas	41
16	Neuropsychiatric Adverse Events With Ritonavir-Boosted Darunavir Monotherapy in HIV-Infected Individuals: A Randomised Prospective Study 2010 ·HIV Clinical Trials ·Alan Winston,Gerd Fätkenheuer,José Ramón Arribas,Andrew Hill,Yvon van Delft,Christiane Moecklinghoff	13
17	A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population 2010 ·AIDS ·Mark Nelson,Hans-Jürgen Stellbrink,Daniel Podzamczer,Dénes Bánhegyi,Brian Gazzard,Andrew Hill,Yvon van Delft,Johan Vingerhoets,Thomas Stark,(unknown)	30
18	The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml 2009 ·AIDS ·José Ramón Arribas,Andrzéj Horban,Jan Gerstoft,(unknown),Mark Nelson,Nathan Clumeck,Federico Pulido,Andrew Hill,Yvon van Delft,Thomas Stark,Christiane Moecklinghoff	140
19	Sustained HIV RNA suppression after switching from enfuvirtide to etravirine in the early access programme 2009 ·Journal of Antimicrobial Chemotherapy ·Mona Loutfy,Esteban Ribera,Éric Florence,Stéphane De Wit,Antonella Castagna,Robert J. Ryan,Andrew Hill,(unknown),Yvon van Delft,(unknown)	3
20	Antiretroviral treatment use and HIV-RNA suppression rates for 877 European patients in the etravirine expanded access programme 2008 ·Journal of the International AIDS Society ·Éric Florence,(unknown),Antonella Castagna,Esteban Ribera,(unknown),Robert J. Ryan,(unknown),(unknown),Yvon van Delft	2

About Yvon van Delft

Yvon van Delft is a scholar working on Virology, Infectious Diseases and Emergency Medicine, having authored 28 papers that have together received 481 indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (25 papers), HIV Research and Treatment (24 papers) and HIV/AIDS Research and Interventions (15 papers). The work is most often cited by research in Virology (354 citations), Infectious Diseases (440 citations) and Emergency Medicine (132 citations). Yvon van Delft has collaborated with scholars based in Netherlands, United Kingdom and Germany. Frequent co-authors include Christiane Moecklinghoff, José Ramón Arribas, Mark Nelson, Nathan Clumeck, Andrew Hill, Andrew Hill, Federico Pulido, Thomas Stark, Andrzéj Horban and Jan Gerstoft. Their work appears in journals such as PLoS ONE, AIDS and Journal of Antimicrobial Chemotherapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact